Back to Search Start Over

Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Autoimmune Rheumatic and Non Rheumatic Diseases.

Authors :
Manfredi M
Van Hoovels L
Benucci M
De Luca R
Coccia C
Bernardini P
Russo E
Amedei A
Guiducci S
Grossi V
Bossuyt X
Perricone C
Infantino M
Source :
Journal of personalized medicine [J Pers Med] 2023 Apr 19; Vol. 13 (4). Date of Electronic Publication: 2023 Apr 19.
Publication Year :
2023

Abstract

The soluble urokinase plasminogen activator receptor (suPAR) is the bioactive form of uPAR, a membrane-bound glycoprotein, and it is primarily expressed on the surface of immunologically active cells. Mirroring local inflammation and immune activation, suPAR has gained interest as a potential prognostic biomarker in several inflammatory diseases. Indeed, in many diseases, including cancer, diabetes, cardiovascular diseases, kidney diseases, and inflammatory disorders, higher suPAR concentrations have been associated with disease severity, disease relapse, and mortality. Our review describes and discusses the supporting literature concerning the promising role of suPAR as a biomarker in different autoimmune rheumatic and non-rheumatic diseases.<br />Competing Interests: The authors declare no conflict of interest.

Details

Language :
English
ISSN :
2075-4426
Volume :
13
Issue :
4
Database :
MEDLINE
Journal :
Journal of personalized medicine
Publication Type :
Academic Journal
Accession number :
37109074
Full Text :
https://doi.org/10.3390/jpm13040688